Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) is dated July 29, 2004. The report announces a significant regulatory milestone regarding the company's proposed acquisition of Aventis.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on regulatory approvals and transaction mechanics.
Material Changes and Transaction Status
- FTC Approval: The U.S. Federal Trade Commission (FTC) has accepted a Consent Decree for public comment, clearing the path for Sanofi to complete its acquisition of Aventis.
- Regulatory Timeline: The European Commission previously approved the transaction on April 26, 2004. The transaction will proceed under the timetable set by the Autorite des Marches Financiers (AMF), with the exchange offer for Aventis shares expiring on July 30, 2004.
- Required Divestitures: To satisfy the FTC Consent Decree, Sanofi must divest specific assets, which the company states are not material to the combined Sanofi-Aventis entity:
- Sale of anti-coagulant Arixtra(R) to GlaxoSmithKline.
- Sale of certain Aventis Campto(R) assets to Pfizer Inc.
- Divestiture of a royalty interest in Estorra(TM), an insomnia treatment, held by Aventis.
Guidance, Outlook, and Risks
Outlook: The transaction is expected to close in accordance with the established timetable, subject to the expiration of the exchange offer on July 30, 2004.
Risks and Contingencies: The completion of the acquisition is conditioned on the closing of the exchange offers in the U.S., France, and Germany. Investors are urged to review the Registration Statement on Form F-4 and related prospectuses for detailed terms and conditions.
Key Facts for Investor Verification
- Verify the final expiration date of the exchange offer for Aventis shares (July 30, 2004).
- Confirm the final terms of the divestitures to GlaxoSmithKline, Pfizer, and Sepracor as outlined in the FTC Consent Decree.
- Review the Registration Statement on Form F-4 (File No. 333-112314) for detailed offer terms.
- Monitor the public comment period for the FTC Consent Decree for any potential objections.